Advertisement

Lessons from Suppressive Therapy and Periodic Presumptive Treatment for Bacterial Vaginosis

  • Jennifer E. BalkusEmail author
  • Kayla A. Carter
  • R. Scott McClelland
Female Genital Tract Infections (J Sobel, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Female Genital Tract Infections

Abstract

Purpose of Review

Suppressive therapy and periodic presumptive treatment (PPT) are distinct but related strategies that have been used to reduce the incidence of bacterial vaginosis (BV). Here, we review clinical trial evidence of the effectiveness of suppressive therapy and PPT to reduce BV, and discuss their roles for women who frequently experience symptomatic or asymptomatic BV.

Recent Findings

Among women who were recently and successfully treated for symptomatic BV, suppressive therapy with twice-weekly metronidazole gel for 16 weeks reduces the likelihood of recurrent symptomatic BV and is currently recommended by the Centers for Disease Control and Prevention for prevention of recurrent BV. The premise of PPT is to provide regimens used to treat BV at regular intervals to reduce the overall frequency of BV, regardless of symptoms. Three PPT trials were conducted using different routes (oral or intravaginal), doses, and frequencies of administration. Each trial demonstrated a significant reduction in BV over the course 12 months, ranging from a 10 to 45% decrease. PPT regimens that substantially reduce the frequency of BV over time could be evaluated in clinical trials to assess whether a reduced frequency of BV leads to subsequent reductions in BV-associated sequelae. While both suppressive therapy and PPT reduce BV, their impact wanes following cessation of the regimen.

Summary

Given the high prevalence of BV globally and burden of adverse reproductive health outcomes among women with BV, there is a critical need for more effective treatments that produce durable shifts in the microbiota towards vaginal health.

Keywords

Bacterial vaginosis Periodic presumptive treatment Suppressive therapy Symptomatic Asymptomatic 

Notes

Compliance with Ethical Standards

Conflict of Interest

JEB has received honoraria for consulting from BD and Lupin Pharmaceuticals. RSM currently receives research funding from Hologic/Gen-Probe and has received honoraria for consulting from Lupin Pharmaceuticals.

All other authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Hillier S. Bacterial Vaginosis. In: Holmes KKSP, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M, Watts D, editors. Sexually transmitted diseases. New York: McGraw-Hill; 2008.Google Scholar
  2. 2.
    Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008;22:1493–501.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Brotman RM, Klebanoff MA, Nansel TR, Yu KF, Andrews WW, Zhang J, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis. 2010;202:1907–15.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Balkus JE, Richardson BA, Rabe LK, Taha TE, Mgodi N, Kasaro MP, et al. Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis. 2014;41:123–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Lokken EM, Balkus JE, Kiarie J, Hughes JP, Jaoko W, Totten PA, et al. Recent bacterial vaginosis is associated with acquisition of mycoplasma genitalium. Am J Epidemiol. 2017;186:194–201.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Cherpes TL, Meyn LA, Krohn MA, Hillier SL. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis. 2003;30:405–10.PubMedGoogle Scholar
  7. 7.
    Tamarelle J, Thiebaut ACM, de Barbeyrac B, Bebear C, Ravel J, Delarocque-Astagneau E. The vaginal microbiota and its association with human papillomavirus, chlamydia trachomatis, Neisseria gonorrhoeae and mycoplasma genitalium infections: a systematic review and meta-analysis. Clin Microbiol Infect 2018.Google Scholar
  8. 8.
    Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med. 1995;333:1737–42.PubMedGoogle Scholar
  9. 9.
    Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA, Holmes KK. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome. JAMA. 1986;256:1899–903.PubMedGoogle Scholar
  10. 10.
    Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol. 1990;75:52–8.PubMedGoogle Scholar
  11. 11.
    Haggerty CL, Hillier SL, Bass DC, Ness RB. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis. 2004;39:990–5.PubMedGoogle Scholar
  12. 12.
    Watts DH, Eschenbach DA, Kenny GE. Early postpartum endometritis: the role of bacteria, genital mycoplasmas, and Chlamydia trachomatis. Obstet Gynecol. 1989;73:52–60.PubMedGoogle Scholar
  13. 13.
    Hillier SL, Kiviat NB, Hawes SE, Hasselquist MB, Hanssen PW, Eschenbach DA, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecol. 1996;175:435–41.PubMedGoogle Scholar
  14. 14.
    Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med. 1988;319:972–8.PubMedGoogle Scholar
  15. 15.
    Larsson PG, Platz-Christensen JJ, Thejls H, Forsum U, Pahlson C. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol. 1992;166:100–3.PubMedGoogle Scholar
  16. 16.
    Haggerty CL, Totten PA, Tang G, Astete SG, Ferris MJ, Norori J, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2016;92:441–6.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46:304–11.PubMedGoogle Scholar
  18. 18.
    Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LAR, Yang LP, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998;12:1699–706.PubMedGoogle Scholar
  19. 19.
    van de Wijgert JH, Morrison CS, Cornelisse PG, et al. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2008;48:203–10.PubMedGoogle Scholar
  20. 20.
    Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007;109:114–20.PubMedGoogle Scholar
  21. 21.
    Martin HL Jr, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053–9.PubMedGoogle Scholar
  22. 22.
    Martin HL Jr, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999;180:1863–8.PubMedGoogle Scholar
  23. 23.
    van de Wijgert JH, Morrison CS, Brown J, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis. 2009;36:357–64.PubMedGoogle Scholar
  24. 24.
    McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008;197:1361–8.PubMedPubMedCentralGoogle Scholar
  25. 25.
    McClelland RS, Richardson BA, Graham SM, et al. A prospective study of risk factors for bacterial vaginosis in HIV-1-seronegative African women. Sex Transm Dis. 2008;35:617–23.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Fettweis JM, Brooks JP, Serrano MG, Sheth NU, Girerd PH, Edwards DJ, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2014;160:2272–82.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 2015;64:1–138.Google Scholar
  28. 28.
    Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009:CD006055.Google Scholar
  29. 29.
    Koumans EH, Markowitz LE, Hogan V, Group CBW. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis. 2002;35:S152–72.PubMedGoogle Scholar
  30. 30.
    Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193:1478–86.PubMedGoogle Scholar
  31. 31.
    Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013;8:e74378.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Bilardi J, Walker S, McNair R, Mooney-Somers J, Temple-Smith M, Bellhouse C, et al. Women’s management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One. 2016;11:e0151794.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Payne SC, Cromer PR, Stanek MK, Palmer AA. Evidence of African-American women’s frustrations with chronic recurrent bacterial vaginosis. J Am Acad Nurse Pract. 2010;22:101–8.PubMedGoogle Scholar
  34. 34.
    Mitchell C, Manhart LE, Thomas K, Fiedler T, Fredricks DN, Marrazzo J. Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol. 2012;2012:706540.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med. 2008;149:20–8.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(97):e1–6.Google Scholar
  37. 37.
    Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106:1013–23.PubMedGoogle Scholar
  38. 38.
    Liu CM, Hungate BA, Tobian AA, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. mBio. 2015;6:e00589.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Zozaya M, Ferris MJ, Siren JD, Lillis R, Myers L, Nsuami MJ, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome. 2016;4:16.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Vodstrcil LA, Walker SM, Hocking JS, Law M, Forcey DS, Fehler G, et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis. 2015;60:1042–53.PubMedGoogle Scholar
  41. 41.
    Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194:1283–9.PubMedGoogle Scholar
  42. 42.
    Balkus JE, Jaoko W, Mandaliya K, Richardson BA, Masese L, Gitau R, et al. The posttrial effect of oral periodic presumptive treatment for vaginal infections on the incidence of bacterial vaginosis and Lactobacillus colonization. Sex Transm Dis. 2012;39:361–5.PubMedPubMedCentralGoogle Scholar
  43. 43.
    McClelland RS, Balkus JE, Lee J, et al. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. J Infect Dis. 2015;211:1875–82.PubMedGoogle Scholar
  44. 44.
    Kim H, Gurrin L, Ademi Z, Liew D. Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br J Clin Pharmacol. 2014;77:116–21.PubMedGoogle Scholar
  45. 45.
    Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22.PubMedGoogle Scholar
  46. 46.
    Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract. 1995;41:443–9.PubMedGoogle Scholar
  47. 47.
    Mochache V, McClelland RS, Balkus JE. Periodic presumptive treatment for women with prevalent vaginal infections: secondary analysis of data from a randomized controlled trial. Sex Transm Dis. 2014;41:453.PubMedPubMedCentralGoogle Scholar
  48. 48.
    World Health Organization (WHO). Guideline for the management of sexually transmitted infections. Geneva: WHO; 2003. p. 1–91.Google Scholar
  49. 49.
    Balkus JE, Srinivasan S, Anzala O, Kimani J, Andac C, Schwebke J, et al. Impact of periodic presumptive treatment for bacterial vaginosis on the vaginal microbiome among women participating in the preventing vaginal infections trial. J Infect Dis. 2017;215:723–31.PubMedGoogle Scholar
  50. 50.
    Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents. 2018;51:319–25.PubMedGoogle Scholar
  51. 51.
    Cunningham FE, Kraus DM, Brubaker L, Fischer JH. Pharmacokinetics of intravaginal metronidazole gel. J Clin Pharmacol. 1994;34:1060–5.PubMedGoogle Scholar
  52. 52.
    Hanson JM, McGregor JA, Hillier SL, Eschenbach DA, Kreutner AK, Galask RP, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med. 2000;45:889–96.PubMedGoogle Scholar
  53. 53.
    Sobel J. Bacterial vaginosis: treatment. www.uptodate.com; Accessed 1 July 2019 2019; Last updated Feb 21, 2019.Google Scholar
  54. 54.
    Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 2011;86:1113–23.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2004;191:1124–9.PubMedGoogle Scholar
  56. 56.
    Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899–911.Google Scholar
  57. 57.
    Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4680–7.Google Scholar
  58. 58.
    Ahmed A, Earl J, Retchless A, Hillier SL, Rabe LK, Cherpes TL, et al. Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars. J Bacteriol. 2012;194:3922–37.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Balashov SV, Mordechai E, Adelson ME, Gygax SE. Identification, quantification and subtyping of Gardnerella vaginalis in noncultured clinical vaginal samples by quantitative PCR. J Med Microbiol. 2014;63:162–75.PubMedGoogle Scholar
  60. 60.
    Cornejo OE, Hickey RJ, Suzuki H, Forney LJ. Focusing the diversity of Gardnerella vaginalis through the lens of ecotypes. Evol Appl. 2018;11:312–24.PubMedGoogle Scholar
  61. 61.
    Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW. Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis. Diagn Microbiol Infect Dis. 2016;84:1–3.PubMedGoogle Scholar
  62. 62.
    Deng ZL, Gottschick C, Bhuju S, Masur C, Abels C, Wagner-Dobler I. Metatranscriptome analysis of the vaginal microbiota reveals potential mechanisms for protection against metronidazole in bacterial vaginosis. mSphere. 2018;3.Google Scholar
  63. 63.
    Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196:517 e1–6.Google Scholar
  64. 64.
    Balkus JE, Manhart LE, Lee J, Anzala O, Kimani J, Schwebke J, et al. Periodic presumptive treatment for vaginal infections may reduce the incidence of sexually transmitted bacterial infections. J Infect Dis. 2016;213:1932–7.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Hilbert DW, Smith WL, Paulish-Miller TE, Chadwick SG, Toner G, Mordechai E, et al. Utilization of molecular methods to identify prognostic markers for recurrent bacterial vaginosis. Diagn Microbiol Infect Dis. 2016;86:231–42.PubMedGoogle Scholar
  66. 66.
    Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194:828–36.PubMedGoogle Scholar
  67. 67.
    Balkus J, Srinivasan S, Andac C, et al. Impact of baseline vaginal bacterial colonization on subsequent development of bacterial vaginosis among women receiving periodic presumptive treatment for vaginal infections. Presented at the Infectious Dieseases Society of Obstetrics and Gynecology, Philadelphia, PA, 2018 2018.Google Scholar
  68. 68.
    Sobel JD, Kaur N, Woznicki NA, Boikov D, Aguin T, Gill G, Akins RA Prognostic indicators of recurrence of bacterial vaginosis. J Clin Microbiol 2019;57.Google Scholar
  69. 69.
    Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis. 2019;68:803–9.PubMedGoogle Scholar
  70. 70.
    Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010;37:745–50.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jennifer E. Balkus
    • 1
    • 2
    • 3
    Email author
  • Kayla A. Carter
    • 1
  • R. Scott McClelland
    • 1
    • 2
    • 4
  1. 1.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  2. 2.Department of Global HealthUniversity of WashingtonSeattleUSA
  3. 3.Vaccine and Infectious Disease DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  4. 4.Department of MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations